PROKIDNEY CP (PROK)
(Delayed Data from NSDQ)
$1.70 USD
+0.14 (9.00%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.70 +0.01 (0.29%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
PROK 1.70 +0.14(9.00%)
Will PROK be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PROK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PROK
Play Likely Earnings Beat With 3 Top-Ranked Stocks
Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now
PROK: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)
ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for PROK
Maintaining Hold on ProKidney: Balancing Potential Against Need for Further Efficacy Data
ProKidney initiated with neutral view at JPMorgan, here's why
Wall Street Breakfast: The Week Ahead
Catalyst Watch: Tesla deliveries, Nike earnings, port strike threat and the jobs report
ProKidney initiated with bullish view at Guggenheim, here's why